Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
Pfizer is shifting creative duties on smoking-cessation drug Chantix to mcgarrybowen from McCann HumanCare, the client confirmed today.
Major media spending on the drug totaled $55 milllion in 2007 and nearly $60 million in the first 11 months of 2008, according to Nielsen Monitor-Plus.
Interpublic Group’s McCann HumanCare in New York had handled the business since 2007.
Chantix, which was approved by the Federal Drug Administration in 2006, rang up global sales of $883 million in 2007, its first full year on the market, according to a Pfizer annual report.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in